James Rolke – Director and Chief Executive Officer Mr. Rolke cofounded and has been the CEO of Revelation since its inception. Mr. Rolke has 29 years of experience in the biotechnology industry, spanning all areas and phases of drug development. Prior to Revelation, beginning in 2012, Mr. Rolke was employed at La Jolla Pharmaceutical Company (La Jolla) in various leadership roles overseeing Research and Development and serving as Chief Scientific Officer from 2017 to 2020. While at La Jolla, Mr. Rolke oversaw the development of multiple technologies including 6 INDs and 2 marketing approvals; Giapreza for the treatment of distributive shock (US FDA and EMEA) and artesunate for the treatment of severe malaria. Prior to La Jolla, from July 2009 to January 2012 Mr. Rolke was Chief Technology Officer at Pluromed, Inc. (acquired by Sanofi) and played a key role in the approvals of two medical devices via the 510(k) and PMA approval pathways. Prior to Pluromed, Mr. Rolke held several key positions at biotechnology companies, including Director of Operations at Prospect Therapeutics, Inc., Associate Director of Pharmaceutical Development at Mersana Therapeutics, Inc., Manager of Process Development at GlycoGenesys, Inc., Principal Scientist at Surgical Sealants, Inc., Scientist at GelTex, Inc., and Associate Scientist at Alpha-Beta Technology, Inc. Mr. Rolke received his B.S. in chemistry from Keene State College. 

Chester Zygmont, III – Chief Financial Officer Mr. Zygmont brings over 20 years of experience in finance to the company with a wide range of industry applications. Since 2016, Mr. Zygmont has been building Jivanas, a social enterprise that owns and operates a factory in Nepal helping create jobs for people at risk for human trafficking. Jivanas has operations in Nepal, Hong Kong, and the USA. During 2013, Mr. Zygmont started oOxesis Biotechnology LLC, a biologics lab that worked on developing therapies for unmet needs. From June 2012 to January 2016, Mr. Zygmont was the Interim CFO and Senior Director of Finance at La Jolla Pharmaceutical Company (La Jolla). During Mr. Zygmont’s tenure at La Jolla, he brought the company to its NASDAQ listing. Prior to La Jolla, Mr. Zygmont served as Managing Director at Z3 Capital, LLC from March 2009 to June 2012. Z3 Capital, LLC, a privately held investment firm, focused on investment acquisition and venture funding for multiple startup companies in real estate, medical device and biotechnology. Mr. Zygmont also served as Vice President at Symmetry Advisors, Inc., a private equity leveraged buyout firm. While at Symmetry, he managed finance for its public sector fund, was a key player on a $600 million buyout of a portfolio company, and subsequently led the restructuring of its manufacturing division. Mr. Zygmont earned his M.S. in Finance from Baruch College, Zicklin School of Business and his B.A. from Eastern University. 

Robin Marsden – Vice President, Biology Ms. Marsden has over 25 years of experience in biotechnology, which has included executing the successful bioanalytical and immunogenicity strategy supporting three FDA-approved products: Symlin and Byetta (both, Astra-Zeneca (previously Amylin)), and Giapreza (La Jolla Pharmaceutical). Robin’s experience includes drug development for a wide variety of molecules including biotherapeutics, peptides, small molecules, PEGylated therapeutics, and antibody drug conjugates (ADCs). Most recently, in her role as Senior Director of La Jolla Pharmaceutical, Robin oversaw a team of twelve research associates and scientists, all responsible for preclinical, bioanalytical, and biologics disciplines supporting multiple La Jolla programs. Currently, Robin is supporting all R&D related activities at Revelation Biosciences, including providing scientific rationale to support corporate strategy, writing patents and regulatory submissions, and overseeing outsourced activities. Robin earned her Bachelor of Sciences degree in Biology from San Diego State University.

Carol Odle – Vice President, Clinical Operations Ms. Odle has over 30 years of clinical research experience including 9 years of global clinical leadership at pharmaceutical companies, 8 years at clinical research organizations (CROs), 3 years as an executive director/partner of a clinical research site, and several years as a manager and study coordinator for multiple clinical trials. Prior to joining Revelation Biosciences, Ms. Odle was Director of Clinical Projects at La Jolla Pharmaceutical Company where she implemented and provided leadership and oversight of global clinical trials including the global trial for the FDA approved product, Giapreza.  Ms. Odle attended Skagit Valley College, Laurel School (Certified Clinical Medical Assistant) and the University of Phoenix.   

Sandra Vedrick – Vice President, Human Resources and Investor Relations For the 6 years prior to joining Revelation Biosciences, Ms. Vedrick was Senior Director and Head of Investor Relations and Human Resources at La Jolla Pharmaceutical Company (La Jolla). While at La Jolla, she lead a team that delivered full-scale HR, IR and corporate communications support across all functions in the company, including the discovery, finance, development and commercial teams. She helped grow the company from 8 employees to over 300 throughout the US, including the on-boarding of 94 commercial sales professionals in a single day. She received her Bachelor of Law degree at the Mykolas Romeris University in Lithuania and her Diploma of Marketing and Advanced Diploma of Business at the Australian Institute of Professional Education.